Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Amanda Evelo"'
Autor:
Imke H. Bartelink, Pierre M. Bet, Nicolas Widmer, Monia Guidi, Erik Duijvelaar, Bram Grob, Richard Honeywell, Amanda Evelo, Ivo P. E. Tielbeek, Sue D. Snape, Henrike Hamer, Laurent A. Decosterd, Harm Jan Bogaard, Jurjan Aman, Eleonora L. Swart
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1497-1511 (2021)
Abstract This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID‐19). Total (bound + unbound) and unbound imatinib pl
Externí odkaz:
https://doaj.org/article/84259887a4a245ea94b698c03f036179
Autor:
Ivo P E Tielbeek, Richard Honeywell, Bram Grob, Pierre M Bet, Harm Jan Bogaard, Monia Guidi, Erik Duijvelaar, Imke H Bartelink, Eleonora L Swart, Nicolas Widmer, Laurent A. Decosterd, Jurjan Aman, Amanda Evelo, Sue D Snape, Henrike Hamer
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT, vol. 10, no. 12, pp. 1497-1511
Bartelink, I H, Bet, P M, Widmer, N, Guidi, M, Duijvelaar, E, Grob, B, Honeywell, R, Evelo, A, Tielbeek, I P E, Snape, S D, Hamer, H, Decosterd, L A, Bogaard, H J, Aman, J & Swart, E L 2021, ' Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials : lessons from the CounterCovid-imatinib-study ', CPT: Pharmacometrics and Systems Pharmacology, vol. 10, no. 12, pp. 1497-1511 . https://doi.org/10.1002/psp4.12718
CPT: Pharmacometrics and Systems Pharmacology, 10(12), 1497-1511. Wiley-Blackwell
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1497-1511 (2021)
CPT, vol. 10, no. 12, pp. 1497-1511
Bartelink, I H, Bet, P M, Widmer, N, Guidi, M, Duijvelaar, E, Grob, B, Honeywell, R, Evelo, A, Tielbeek, I P E, Snape, S D, Hamer, H, Decosterd, L A, Bogaard, H J, Aman, J & Swart, E L 2021, ' Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials : lessons from the CounterCovid-imatinib-study ', CPT: Pharmacometrics and Systems Pharmacology, vol. 10, no. 12, pp. 1497-1511 . https://doi.org/10.1002/psp4.12718
CPT: Pharmacometrics and Systems Pharmacology, 10(12), 1497-1511. Wiley-Blackwell
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1497-1511 (2021)
This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID-19). Total (bound + unbound) and unbound imatinib plasma concen